Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients

European Journal of Clinical Pharmacology

Volumn 59, Issue 11, 2004, Pages 783-790

  El Desoky, Ehab S ^a   Fuseau, Eliane ^b   El Din Amry, Salah ^c   Cosson, Valérie ^b  

^a Assiut University Faculty of Medicine   (Egypt)

^b EMF Consulting   (France)

^c ASSIUT UNIVERSITY   (Egypt)

Author keywords

Epileptic patients; Population pharmacokinetics; Valproic acid

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; CHILD; COMPUTER PROGRAM; CONTROLLED STUDY; COVARIANCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; EGYPT; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ADOLESCENT; ADULT; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; DRUG INTERACTIONS; EGYPT; EPILEPSY; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; RETROSPECTIVE STUDIES; VALPROIC ACID;

EID: 1242314820     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0699-7     Document Type: Article

References (38)

1. Sundqvist A, Tomson T, Lundkvist B (1997) Pharmacokinetics of valproic acid in patients with myoclonic epilepsy on monotherapy. Ther Drug Monit 9:153-159
2. Yukawa E (1996) Optimisation of antiepileptic drug therapy. Clin Pharmacokinet 31:120-130
3. EL Desoky E, Kandil MR, Afifi AHM, Mostafa OA (1999) Spotlight on the continual applicability of routine plasma monitoring antiepileptic drugs in the treatment of epilepsy. Pharmacol Res 39:269-274
4. Cloyd JC, Fisher JH, Kriel RL, Kraus DM (1993) Valproic acid pharmacokinetics in children. IV: Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther 53:22-29
5. Tisdale JE, Tsuyuki RT, Oles KS, Penry JK (1992) Relationship between serum concentration and dose of valproic acid during monotherapy in adult outpatients. Ther Drug Monit 14:416-443
6. Gidal BE, Pitterle ME, Spencer NW, Maly MM (1995) Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. Clin Pharmacol Ther 20:215-219
7. Sheiner LB, Rosenberg B, Marathe VV (1977) Estimation of population characteristics of pharmacokinetic parameter from routine clinical data. J Pharmacokinet Biopharm 5:445-479
8. Grasela TH, Sheiner LB (1991) Pharmacostatistical modeling for observational data. J Pharmacokinet Biopharm 19:25S-36S
9. Beal SL, Sheiner LB (1992) NONMEM User's Guides. NON-MEM Project Group, University of California, San Francisco
10. Davis R, Peters DV, McTavish D (1994) Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47:332-372
11. Thummel KE, Shen DD (2001) Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman JG, Limbird LE, Gilman AG (eds) Goodman & Gilman's The pharmacological basis of therapeutics 2001, 10th edn. McGraw-Hill, New York, Appendix II pp 1917-2023
12. Hogg R, Tanis E (1977) Probability and statistical inference, Macmillan Publishing Company, New York, p 393
13. Zar J (1974) Biostatistical analysis, Prentice Hall, Upper Saddle River, p 54
14. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512
15. Ette E, Kelman AW, Howie CA, Whiting B (1995) Analysis of animal pharmacokinetic data: performance of one point per animal design. J Pharmacokinet Biopharm 23:551-566
16. Blanco Serrano B, Garcia Sanchez MJ, Otero MJ, Santos Buelga D, Serrano J, Dominguez-Gil A (1999) Valproate population pharmacokinetics in children. J Clin Pharm Ther 24:73-80
17. Blanco Serrano B, Otero MJ, Santos Buelga D, Garcia Sanchez MJ, Serrano J, Dominguez-Gil A (1999) Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos 20:233-240
18. Park HM, Kang SS, Lee YB, Shin DJ, Kim ON, Lee SB, Yim DS (2003) Population pharmacokinetics of intravenous valproic acid in Korean patients. J Clin Pharm Ther 27:419-425
19. Breant V, Charpiat B, Sab JM, Maire P, Jelliffe RW (1996) How many patients and blood levels are necessary for population pharmacokinetic analysis? A study of a one compartment model applied to cyclosporine. Eur J Clin Pharmacol 51:283-288
20. Niclas Jonsson E, Wade JR, Karlsson MO (1996) Comparison of some practical sampling strategies for population pharmacokinetic studies. J Pharmacokinet Biopharm 24:245-263
21. Hing JP, Woolfrey SG, Wright PM (2001) Is mixed effects modeling or na pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data? J Pharmacokinet Pharmacodyn 28:193-210
22. Thomson AH, Brodie MJ (1992) Pharmacokinetic optimization of anticonvulsant therapy. Clin Pharmacokinet 23:216-230
23. Zaccara M, Messori A, Moroni F (1988) Clinical pharmacokinetics of valproic acid - 1988. Clin Pharmacokinet 15:367-389
24. Sanchez-Alcara ZA, Quintana MB, Lopez E, Rodriguez I (1998) Valproic acid clearance with epilepsy. J Clin Pharm Ther 23:31-34
25. Perucca E, Gotti G, Frigo GM, Crema A (1978) Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 5:313-318
26. Klotz U, Antonin KH (1977) Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther 21:736-743
27. Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T (1997) Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol 37:1160-1167
28. Chiba K, Suganuma T, Ishizaki T, Iriki T, Hori M (1985) Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug therapy. J Pediatr 106:653-658
29. Hall K, Otten N, Johnston B, Irvine-Meek J, Leroux M, Seshia S (1985) A multivariable analysis of factors governing the steady-state pharmacokinetics of valproic acid in 52 young epileptics. J Clin Pharmacol 25:261-268
30. Gugler R, Schell A, Eichelbaum M (1977) Disposition of valproic acid in man. Eur J Clin Pharmacol 12:125-132
31. Bowdle TA, Patel IH, Levy RH, Wilensky AJ (1980) Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther 28:486-492
32. Cramer JA, Mattson RH (1979) Valproic acid: in vitro plasma protein binding and interactions with phenytoin. Ther Drug Monit 1:105-116
33. May T, Rambeck B (1982) Serum concentrations of valproic acid: influence of dose and comedication. Ther Drug Monit 7:387-390
34. Brodie MJ (1992) Drug interactions in epilepsy. Epilepsia 33[Suppl]:S13-S22
35. Yukawa E, Honda T, Ohdo S, Higuchi S, Aoyama T (1997) Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening. J Pharm Pharmacol 49:751-756
36. Botha JH, Gray AL, Miller R (1995) A model for estimating individualized valproate clearance values in children. J Clin Pharmacol 35:1020-1024
37. Yukawa E (1995) A feasibility study of the multiple-peak approach for pharmacokinetic screening: population based investigation of valproic acid relative clearance using routine clinical pharmacokinetic data. J Pharm Pharmacol 47:1048-1052
38. Cloyd JC, Brundage RC (1986) Valproic acid. In: Taylor W, Diers-Caviness NH (eds) A textbook for the clinical application of therapeutic drug monitoring. Abbott Laboratories. Irvine, pp 269-280